TRUTAKNA meets all endpoints in ORIGIN 3 final analysis; stabilizes eGFR, cuts progression risk 76%

Vera Therapeutics, Inc.

Mean eGFR change at 52 weeks: TRUTAKNA -0.1 vs placebo -5.7 mL/min/1.73m² (treatment effect 5.6, p<0.0001).
Annualized eGFR slope to 104 weeks: -0.6 vs -5.6 mL/min/1.73m²/yr (effect 5.0, p<0.0001).
Composite kidney progression events: 11 vs 38; HR 0.24 (95% CI 0.12-0.48), 76% risk reduction (p<0.0001).
No dialysis/transplant/death events in TRUTAKNA arm vs 8 on placebo through 104 weeks; safety comparable to placebo.
Over 350 patient start forms in first 10 weeks of launch; sBLA for full FDA approval planned Q4 2026.

Featured in Daily 8-K Digest

Selected #8 for 2026-09-15. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.